OverviewSuggest Edit

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.
TypePublic
Founded2001
HQMilton, GB
Websiteoxfordimmunotec.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Feb 2019)414(-5%)
Job Openings4
Revenue (FY, 2017)£77.6 M(+20%)
Share Price (Mar 2019)$17.5 (-2%)

Key People/Management at Oxford Immunotec

Peter Wrighton-Smith

Peter Wrighton-Smith

CEO
Richard M. Altieri

Richard M. Altieri

CFO
Show more

Oxford Immunotec Office Locations

Oxford Immunotec has offices in Milton, Marlborough, Kohoku Ward and Shanghai
Milton, GB (HQ)
115D Innovation Drive Milton Park Abingdon Oxfordshire
Shanghai, CN
1701, Tower 2, Shanghai Arch Hongqiao, 533 Loushanguang Road
Kohoku Ward, JP
8F Nisso Bldg. No16, 3-8-8 Shinyokohama
Marlborough, US
700 Nickerson Rd #200, Marlborough
Show all (4)
Report incorrect company information

Oxford Immunotec Financials and Metrics

Oxford Immunotec Revenue

Embed Graph
View revenue for all periods
Oxford Immunotec's revenue was reported to be £77.65 m in FY, 2017
GBP

Revenue (FY, 2017)

77.6m

Gross profit (FY, 2017)

42.4m

Gross profit margin (FY, 2017), %

54.6%

Net income (FY, 2017)

(25.8m)

EBITDA (FY, 2017)

(38.4m)

EBIT (FY, 2017)

(40.8m)

Market capitalization (22-Mar-2019)

463.7m

Closing stock price (22-Mar-2019)

17.5

Cash (31-Dec-2017)

68.0m
Oxford Immunotec's current market capitalization is $463.7 m.
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

12.1m25.5m36.6m48.6m64.8m77.6m

Revenue growth, %

44%27%

Cost of goods sold

7.3m12.2m17.8m22.9m29.6m35.2m

Gross profit

4.8m13.3m18.9m25.7m35.2m42.4m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

7.8m50.6m37.4m64.9m44.5m68.0m

Accounts Receivable

3.2m3.1m5.0m5.5m10.0m12.8m

Inventories

1.8m3.6m4.8m5.5m5.7m7.7m

Current Assets

13.5m58.8m49.2m78.7m62.0m90.8m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(8.7m)(5.7m)(16.4m)(19.0m)(16.7m)(25.8m)

Cash From Operating Activities

(3.7m)(15.4m)(12.8m)(16.5m)(2.9m)

Cash From Financing Activities

46.5m(111.7k)41.6m21.9m29.8m

Net Change in Cash

41.6m(19.2m)26.3m(17.2m)23.2m
GBPY, 2017

Revenue/Employee

172.4k

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information

Oxford Immunotec Online and Social Media Presence

Embed Graph
Report incorrect company information

Oxford Immunotec News and Updates

Oxford Immunotec Reports Fourth Quarter and Full Year 2018 Financial Results

OXFORD, United Kingdom and MARLBOROUGH, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, today announced fourth quarter and full year 2018 financial results.

Oxford Immunotec Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for March 11, 2019

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2018 financial results after the close of the…

Oxford Immunotec Announces Board Approval of $100 Million Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that its Board of Directors has approved a share purchase program, which would involve the purchase…

Oxford Immunotec Announces Regulatory Acceptance of T-Cell Select™ in China

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced regulatory acceptance of the T-Cell Select kit by the China Food and Drug Administration (CFDA).

Oxford Immunotec to Participate in Two Investor Conferences This Week

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following investor conferenc…

Oxford Immunotec Reports Third Quarter 2018 Financial Results

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced third quarter 2018 financial results.
Show more
Report incorrect company information

Oxford Immunotec Frequently Asked Questions

  • When was Oxford Immunotec founded?

    Oxford Immunotec was founded in 2001.

  • Who are Oxford Immunotec key executives?

    Oxford Immunotec's key executives are Peter Wrighton-Smith and Richard M. Altieri.

  • How many employees does Oxford Immunotec have?

    Oxford Immunotec has 414 employees.

  • What is Oxford Immunotec revenue?

    Latest Oxford Immunotec annual revenue is £77.6 m.

  • What is Oxford Immunotec revenue per employee?

    Latest Oxford Immunotec revenue per employee is £187.6 k.

  • Who are Oxford Immunotec competitors?

    Competitors of Oxford Immunotec include Thriva, OncoCyte and Immucor.

  • Where is Oxford Immunotec headquarters?

    Oxford Immunotec headquarters is located at 115D Innovation Drive Milton Park Abingdon Oxfordshire, Milton.

  • Where are Oxford Immunotec offices?

    Oxford Immunotec has offices in Milton, Marlborough, Kohoku Ward and Shanghai.

  • How many offices does Oxford Immunotec have?

    Oxford Immunotec has 4 offices.